Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions

被引:42
|
作者
Dovonou, Axelle [1 ]
Bolduc, Cyril [1 ]
Linan, Victoria Soto [1 ]
Gora, Charles [1 ]
Peralta, Modesto R. R. [1 ]
Levesque, Martin [1 ,2 ]
机构
[1] CERVO Brain Res Ctr, 2601, Chemin Canardiere, Quebec City, PQ G1J 2G3, Canada
[2] Univ Laval, Fac Med, Dept Psychiat & Neurosci, Quebec City, PQ, Canada
基金
加拿大健康研究院;
关键词
Parkinson's disease; Animal model; Alpha-synuclein; Transgenic model; Preformed fibril; Mouse; HUMAN ALPHA-SYNUCLEIN; HALOPERIDOL-INDUCED CATALEPSY; MITOCHONDRIAL COMPLEX-I; NIGROSTRIATAL DOPAMINERGIC SYSTEM; VECTOR-MEDIATED OVEREXPRESSION; TRANSCRIPTION FACTORS LMX1A; INDUCED TARDIVE-DYSKINESIA; ENVIRONMENTAL RISK-FACTORS; TRANSGENIC MOUSE MODEL; RAT SUBSTANTIA-NIGRA;
D O I
10.1186/s40035-023-00368-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. More than 200 years after its first clinical description, PD remains a serious affliction that affects a growing proportion of the population. Prevailing treatments only alleviate symptoms; there is still neither a cure that targets the neurodegenerative processes nor therapies that modify the course of the disease. Over the past decades, several animal models have been developed to study PD. Although no model precisely recapitulates the pathology, they still provide valuable information that contributes to our understanding of the disease and the limitations of our treatment options. This review comprehensively summarizes the different animal models available for Parkinson's research, with a focus on those induced by drugs, neurotoxins, pesticides, genetic alterations, & alpha;-synuclein inoculation, and viral vector injections. We highlight their characteristics and ability to reproduce PD-like phenotypes. It is essential to realize that the strengths and weaknesses of each model and the induction technique at our disposal are determined by the research question being asked. Our review, therefore, seeks to better aid researchers by ensuring a concrete discernment of classical and novel animal models in PD research.
引用
收藏
页数:25
相关论文
共 50 条
  • [31] Animal Models of Parkinson's Disease: Vertebrate Genetics
    Lee, Yunjong
    Dawson, Valina L.
    Dawson, Ted M.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (10):
  • [32] Impact of aging on animal models of Parkinson's disease
    Klaestrup, Ida Hyllen
    Just, Mie Kristine
    Holm, Karina Lassen
    Alstrup, Aage Kristian Olsen
    Romero-Ramos, Marina
    Borghammer, Per
    van den Berge, Nathalie
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [33] Animal Models of Gastrointestinal Problems in Parkinson's Disease
    Greene, James G.
    JOURNAL OF PARKINSONS DISEASE, 2011, 1 (02) : 137 - 149
  • [34] Animal Models of Parkinson's Disease: A Gateway to Therapeutics?
    Le, Weidong
    Sayana, Pavani
    Jankovic, Joseph
    NEUROTHERAPEUTICS, 2014, 11 (01) : 92 - 110
  • [35] A Guide to Neurotoxic Animal Models of Parkinson's Disease
    Tieu, Kim
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2011, 1 (01):
  • [36] Experimental Animal Models of Prodromal Parkinson's Disease
    Yamakado, Hodaka
    Takahashi, Ryosuke
    JOURNAL OF PARKINSONS DISEASE, 2024, 14 : S369 - S379
  • [37] PET imaging in animal models of Parkinson's disease
    Ni, Ruiqing
    BEHAVIOURAL BRAIN RESEARCH, 2023, 438
  • [38] Animal models of Parkinson's disease: An updated overview
    Gubellini, P.
    Kachidian, P.
    REVUE NEUROLOGIQUE, 2015, 171 (11) : 750 - 761
  • [39] Enteric neuropathy in animal models of Parkinson's disease
    McQuade, Rachel M.
    Diwakarla, Shanti
    Di Natale, Madelaine
    Lei, Enie
    Ringuet, Mitchell T.
    Berger, Joel P.
    Kauhausen, Jessica
    Parish, Clare
    Finkelstein, David I.
    Furness, John B.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32
  • [40] Classic and evolving animal models in Parkinson's disease
    Pingale, Tanvi
    Gupta, Girdhari Lal
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2020, 199